Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma-Reference-Cited by-同舟云学术

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

Published:2019-12-10 Issue:3 Volume:9 Page:882-893
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Villalobos Victor M.¹,Mo Gary²,Agulnik Mark³,Pollack Seth M.⁴,Rushing Daniel A.⁵,Singh Arun⁶,Van Tine Brian A.⁷^ORCID,McNaughton Rhian⁸,Decker Rodney L.²,Zhang Wei²,Shahir Ashwin⁸,Cronier Damien M.²

Affiliation:

1. University of Colorado Denver Anschutz Medical Campus Aurora CO USA

2. Eli Lilly and Company Indianapolis IN USA

3. Division of Hematology/Oncology Northwestern University Feinberg School of Medicine Chicago IL USA

4. Division of Oncology Fred Hutchinson Cancer Research Center University of Washington Seattle WA USA

5. Simon Cancer Center Indiana University Medical Center Indianapolis IN USA

6. Division of Hematology‐Oncology University of California Los Angeles CA USA

7. Division of Medical Oncology Department of Internal Medicine Siteman Cancer Center St. Louis School of Medicine St. Louis MO USA

8. Eli Lilly and Company Windlesham Surrey UK

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2728

Reference11 articles.

1. Sarcoma Immunotherapy: Past Approaches and Future Directions

2. The Epidemiology of Sarcoma

3. Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts

4. Lartruvo[package insert].Indianapolis IN:Eli Lilly and Co;2016.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf. Accessed March 27 2019.

5. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species;2023-03-29

2. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma;Molecular Cancer Therapeutics;2020-11-11